A Comparison of Two Assessment Tools in Predicting Treatment Success of Cimzia in Rheumatoid Arthritis Subjects
NCT ID: NCT01255761
Last Updated: 2018-07-31
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
736 participants
INTERVENTIONAL
2010-11-30
2012-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Long Term Effects of an Early Response to Certolizumab Pegol (CZP, Cimzia®) in Rheumatoid Arthritis (RA) Patients
NCT01288287
Can TNF-Alpha Incomplete Secondary Responders Attain a Safe and Efficacious Response Switching to Cimzia
NCT01147341
Observation of Treatment With Certolizumab Pegol in Daily Practice
NCT01069419
A 12 Week Study to Assess Changes in Joint Inflammation Using Ultrasonography in Patients With Rheumatoid Arthritis (RA)
NCT01292265
Rheumatoid Arthritis Treatment and Biopsy Study Assessing Certolizumab Pegol (Cimzia)
NCT01374971
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
RAPID3 to assess response to Cimzia
RAPID3 is a subject-based assessment tool used to assess subject's response to Cimzia.
Subjects will be randomized to a patient measure tool, a tool based on patient-report outcomes (RAPID3); using a total score of 30 points
Certolizumab Pegol (CZP)
400 mg subcutaneous injection at Weeks 0, 2 and 4
200 mg subcutaneous injection every two weeks, Week 6 through Week 52
CDAI to assess response to Cimzia
CDAI is an investigator-based assessment tool used to assess subject's response to Cimzia.
Subjects will be randomized to a clinical measures tool, a tool based on Investigator measures without the need for a lab value (CDAI)
Certolizumab Pegol (CZP)
400 mg subcutaneous injection at Weeks 0, 2 and 4
200 mg subcutaneous injection every two weeks, Week 6 through Week 52
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Certolizumab Pegol (CZP)
400 mg subcutaneous injection at Weeks 0, 2 and 4
200 mg subcutaneous injection every two weeks, Week 6 through Week 52
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects with a diagnosis of Adult-onset Rheumatoid Arthritis of at least 3 months as defined by the 1987 American College of Rheumatology (ACR) classification criteria
* Subjects with active Rheumatoid Arthritis as defined by:
* 4 tender joints (28 joint count) at Screening and Baseline Visits; and
* 4 swollen joints (28 joint count) at Screening and Baseline Visits
* Subjects who have had an unsatisfactory response or intolerance to at least 1 traditional Disease-modifying Antirheumatic Drugs (DMARD)
Exclusion Criteria
* Subjects must not have greater than 3 Arthroplasties due to Rheumatoid Arthritis and/or Steinbrocker IV Functional Capacity
* Subjects must not have a secondary non-inflammatory type of Arthritis that would interfere with study evaluation
* Subjects must not be diagnosed with Fibromyalgia with sufficient symptoms requiring treatment
* Subjects must not have a history of Infected Joint Prosthesis
* Subjects must not have discontinued biological therapy for their Rheumatoid Arthritis due to Severe Hypersensitivity Reaction or Anaphylactic Reaction
* Subjects must not have received more than 2 anti- Tumor Necrosis Factor (TNF) agents prior to enrollment
* Subjects must not have received treatment with Abatacept and/or Rituximab or have received any experimental or approved B cell therapeutic agent
* Subjects must not have a history of chronic alcohol or drug abuse
* Subjects must not have known hypersensitivity to any components of the investigational medicinal product
* Subjects must not have a history of chronic infections, recent serious or life-threatening infection within 6 months or any current sign or symptom that may indicate an infection
* Subjects must not have a history of a Blood Dyscrasias
* Subjects with known Tuberculosis (TB) Disease, high risk of acquiring TB or latent TB infection
* Subjects must not be at high risk of infection
* Subjects must not have a history of Lymphoproliferative Disorder including Lymphoma signs and symptoms suggestive of Lymphoproliferative Disease
* Subjects must not have concurrent acute or chronic Viral Hepatitis B or C
* Subjects must not have known Human Immunodeficiency Virus (HIV) infection
* Subject must not have concurrent Malignancy or history of Malignancy
* Subjects must not have a current or recent history of severe, progressive, and/or uncontrolled Renal, Hepatic, Hematological, Gastrointestinal, Endocrine, Pulmonary, Cardiac, Neurological or Cerebral Disease
* Subjects must not have Class III or IV Congestive Heart Failure
* Subjects must not have history of, or suspected Demyelinating Disease of the Central Nervous System
* Subjects must not have a history of adverse reaction to Polyethylene Glycol (PEG)
* Subjects must not have significant laboratory abnormalities which in the investigators judgment would make the subject unsuitable for inclusion
* Subjects must not have a known history or clinically active infection with Histoplasma, Coccidiodes, Paracoccidioides, Pneumocystis, Nontuberculous Mycobacteria, Blastomyces or Aspergillus
* Subject must not have a known history of or be currently diagnosed with Systemic Lupus Erythematosus
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
UCB Pharma
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
UCB Clinical Trial Call Center
Role: STUDY_DIRECTOR
+1 877 822 9493 (UCB)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
137
Birmingham, Alabama, United States
166
Huntsville, Alabama, United States
165
Peoria, Arizona, United States
216
Tucson, Arizona, United States
168
Hot Springs, Arkansas, United States
241
Jonesboro, Arkansas, United States
153
Little Rock, Arkansas, United States
111
Covina, California, United States
208
Escondido, California, United States
103
Fullerton, California, United States
155
Huntington Beach, California, United States
202
La Mesa, California, United States
203
Loma Linda, California, United States
233
Los Angeles, California, United States
105
Palm Desert, California, United States
229
Roseville, California, United States
113
Sacramento, California, United States
127
San Diego, California, United States
106
Santa Maria, California, United States
172
Santa Monica, California, United States
212
Upland, California, United States
231
Van Nuys, California, United States
158
Whittier, California, United States
121
Bridgeport, Connecticut, United States
200
Bridgeport, Connecticut, United States
107
Danbury, Connecticut, United States
195
Danbury, Connecticut, United States
138
Hamden, Connecticut, United States
218
Lewes, Delaware, United States
108
Aventura, Florida, United States
120
Dunedin, Florida, United States
101
Ocala, Florida, United States
225
Orange Park, Florida, United States
227
Ormond Beach, Florida, United States
184
Palm Harbor, Florida, United States
145
Sarasota, Florida, United States
191
Tampa, Florida, United States
236
Vero Beach, Florida, United States
144
Atlanta, Georgia, United States
232
Atlanta, Georgia, United States
157
Lawrenceville, Georgia, United States
217
Coeur d'Alene, Idaho, United States
206
Idaho Falls, Idaho, United States
193
Rock Island, Illinois, United States
207
Springfield, Illinois, United States
186
Elizabethtown, Kentucky, United States
204
Lexington, Kentucky, United States
230
Louisville, Kentucky, United States
149
Cumberland, Maryland, United States
237
Hagerstown, Maryland, United States
197
Wheaton, Maryland, United States
118
Mansfield, Massachusetts, United States
132
Worcester, Massachusetts, United States
140
Lansing, Michigan, United States
226
Petoskey, Michigan, United States
114
Saint Clair Shores, Michigan, United States
188
Bridgeton, Missouri, United States
109
St Louis, Missouri, United States
133
St Louis, Missouri, United States
124
Lincoln, Nebraska, United States
205
Reno, Nevada, United States
159
Lebanon, New Hampshire, United States
189
Nashua, New Hampshire, United States
143
Clifton, New Jersey, United States
125
Albuquerque, New Mexico, United States
175
Albany, New York, United States
139
Binghamton, New York, United States
116
Brooklyn, New York, United States
167
Brooklyn, New York, United States
196
Johnson City, New York, United States
174
New York, New York, United States
104
Orchard Park, New York, United States
135
Plainview, New York, United States
215
Rochester, New York, United States
178
Charlotte, North Carolina, United States
210
Durham, North Carolina, United States
234
Hickory, North Carolina, United States
102
Monroe, North Carolina, United States
152
Bethlehem, Pennsylvania, United States
112
Duncansville, Pennsylvania, United States
219
Erie, Pennsylvania, United States
128
Philadelphia, Pennsylvania, United States
147
Sellersville, Pennsylvania, United States
213
Willow Grove, Pennsylvania, United States
235
Wyomissing, Pennsylvania, United States
198
Charleston, South Carolina, United States
228
Columbia, South Carolina, United States
130
Hendersonville, Tennessee, United States
129
Jackson, Tennessee, United States
162
Amarillo, Texas, United States
110
Austin, Texas, United States
156
Austin, Texas, United States
192
Dallas, Texas, United States
185
El Paso, Texas, United States
122
Houston, Texas, United States
170
Houston, Texas, United States
123
Mesquite, Texas, United States
115
Nassau Bay, Texas, United States
117
San Antonio, Texas, United States
119
San Antonio, Texas, United States
161
San Antonio, Texas, United States
190
Victoria, Texas, United States
142
Waco, Texas, United States
136
Burlington, Vermont, United States
146
Arlington, Virginia, United States
150
Chesapeake, Virginia, United States
223
Kennewick, Washington, United States
134
Spokane, Washington, United States
221
Clarksburg, West Virginia, United States
194
Glendale, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Curtis JR, Herrem C, Ndlovu 'N, O'Brien C, Yazici Y. A somatization comorbidity phenotype impacts response to therapy in rheumatoid arthritis: post-hoc results from the certolizumab pegol phase 4 PREDICT trial. Arthritis Res Ther. 2017 Sep 29;19(1):215. doi: 10.1186/s13075-017-1412-z.
Curtis JR, Churchill M, Kivitz A, Samad A, Gauer L, Gervitz L, Koetse W, Melin J, Yazici Y. A Randomized Trial Comparing Disease Activity Measures for the Assessment and Prediction of Response in Rheumatoid Arthritis Patients Initiating Certolizumab Pegol. Arthritis Rheumatol. 2015 Dec;67(12):3104-12. doi: 10.1002/art.39322.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RA0064
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.